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Abstract
Background: Health is recognized as a fundamental right in Brazil’s constitution. In the absence of a clearly defined
benefit packages of healthcare services that are financed under the Unified Health System (Sistema Único de Saúde,
SUS), courts have become important in adjudicating coverage decisions. Empirical assessments of equity and the
right to health tend to focus on simple measures of access. However, these empirical perspectives belie the
significant inequalities and rights violations that arise in the case of more complex health needs such as cancer. To
shed light on these issues, this paper focuses on the care pathways for breast and cervical cancer and explores
access and quality issues that arise at different points along the care pathway with implications for the realization of
the right to health in Brazil.
Method: A mixed method approach is used. The analysis is primarily based on a quantitative analysis of national
representative administrative data principally from the cervical and breast cancer information systems and the
hospital cancer registry. To gain more insights into the organization of cancer care, qualitative data was collected
from the state of Bahia, through document analysis, direct observation, roundtable discussions with health workers
(HWs), and structured interviews with health care administrators.
Results: The paper reveals that the volume of completed screening exams is well below the estimated need, and a
tendency toward lower breast cancer screening rates in poorer states and for women in the lowest income
brackets. Only 26% of breast cancer cases and 29% of cervical cancer cases are diagnosed at an early stage (stage 0
or I), thereby reducing the survival prospects of patients. Waiting times between confirmed diagnosis and
treatment are long, despite new legislation that guarantees a maximum of 60 days. The waiting times are
significantly longer for patients that follow the recommended patient pathways, and who are diagnosed outside
the hospital.
Conclusion: The study reveals that there are large variations between states and patients, where the poorest states
and patients fare worse on key indicators. More broadly, the paper shows the importance of collecting data both
on patient characteristics and health system performance and carry out detailed health system analysis for
exposing, empirically, rights violations and for identifying how they can be addressed.
Keywords: Right to health, Brazil, Bahia, Cancer care, Cervical cancer, Breast cancer, Health system, Brazil’s Unified
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Background
With the prominence given to the achievement of Uni-
versal Health Coverage (UHC) in the Sustainable Devel-
opment Goals framework, the right to health and its
legal enforcement are increasingly relevant [1]. As stated
by the World Health Organization (WHO) UHC is de-
fined as “all people receiving quality health services that
meet their needs without being exposed to financial
hardship in paying for the services” [2]. Thus, UHC is
inclusive of effective coverage, i.e., access to quality
health services (as opposed to insurance coverage) and
protection against financial risk. UHC has been called a
“practical expression of the right to health” [3]. As coun-
tries progress towards UHC, policy-makers face difficult
choices related to which services to expand first and to
whom. Litigation over rights to goods and services will
certainly play a role in how UHC is implemented, particu-
larly in countries where the right to health is encoded in
the national laws [1].
The right to health as set forth in the WHO Constitu-
tion [4] is defined as “the highest attainable standard of
health”. Braveman and Gruskin [5] argue that the high-
est attainable standard of health can be understood to
reflect the standard of health enjoyed by socially advan-
taged groups within a society, since these could be pos-
sible for everyone living in that society. This means that
equity in health helps to operationalize the concept of
the right to health. WHO defines health equity as “the
absence of avoidable, unfair, or remediable differences
among groups of people, whether those groups are de-
fined socially, economically, demographically or geo-
graphically or by other means of stratification” [6].
In the case of Brazil, health is recognized as a funda-
mental right in Brazil’s 1988 constitution and the univer-
sal right to health is a founding principle of the Unified
Health System (Sistema Único de Saúde [SUS]). Guided
by the constitutional principles of universality, compre-
hensiveness/continuity of care and equality of access to
health care, guaranteeing the right to health is a shared
responsibility of Brazil’s three governmental spheres
(federal, state and municipal) [7].
On the one hand, the constitutional right to health can
have positive effect on equity in access to healthcare if indi-
viduals who are denied access to specific medicines or tech-
nologies (due to e.g. health system delivery shortfalls or
delays in inclusion of medications into SUS) turn to the
courts to gain access and thereby uphold the principles of
universality encoded in SUS. On the other hand, judicializa-
tion may increase inequity, if litigation leads to the careless
use of medicines or services, or if individuals with better
socio-economic standing who may last longer in litigation
get priority access to medicines and health services at the
expense of poorer populations. In such instances, litigation
may violate the principles of SUS [7] and ultimately the
power to make public policy is moved from policy-makers
to the courts [8].
The inception of SUS led to profound changes in the
healthcare system in Brazil with significant achieve-
ments, including the rapid expansion of primary care,
the integration of several independent systems of finan-
cing and service provision into a single publicly funded
system, and increases in government spending on health
(with particular focus on basic care) [9]. As a result,
large improvements in health service coverage and
health outcomes have been observed [10, 11]. However,
disparities in access to healthcare and health outcomes
persist, with a higher level of utilization among
high-income groups and unmet healthcare needs in pop-
ulations living in poorer northern regions [9]. Largely,
health inequalities mirror income inequalities in the
country [12].1
To operationalize the right to health in SUS, the gov-
ernment increased the health facility network and main-
tained the legal provision that anyone should have
access to an open-ended benefit package free-of-charge
under the SUS [9]. Effectively, this implies that the gov-
ernment supply any medication judicially ruled, even if
that conflicts with established public policy such as clin-
ical protocols and therapeutic guidelines [13]. The Judi-
ciary has even made recent calls to have clear and
objective parameters regarding which medications are
covered by SUS [ibid].
In the absence of clear standards, consensus or criteria
for which services and technologies should be financed
within SUS, the courts have become important in adjudi-
cating coverage decisions. Right-to-health litigation has in-
creased exponentially. While data at the national level is
not available, data from 7 out of 26 states showed that fed-
eral spending on court-ordered health services increased
40 times since 2005, reaching an estimated USD $550 mil-
lion in 2010 [14]. However, these numbers are not inclu-
sive of most of the costs that occur at the state and
municipal levels. Most cases are individual ones (only
around 3% are collective) that focus on access to health
care services (mostly drugs), and the success rate for these
litigants is high [15]. A growing body of evidence shows
that judicialization accentuates inequalities in the health
system. Most of the court orders are in states with the
highest Human Development Index [15], and evidence
from the municipality of São Paulo show that litigants
tend to originate from the neighborhoods with the lowest
levels of exclusion or social vulnerability [16].2
The legal system may, however, be a slow and costly
mechanism for making decisions about health care
coverage. Whether the right to health is delivered is de-
termined in the more complex world of how services are
organized and delivered, where advances in the right to
health could arguably be made through improvements
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in systems and management in some cases without add-
itional resources. To operationalize the right to health, it
is therefore critical to understand and ensure if and how
the health system is fair [8], and if and how it provides
equal opportunity for all [17].
Empirical assessments of equity and the right to health
tend to emphasize simple measures of access or
utilization of services. Similarly, much of health-related
litigation focuses on access to specific drugs or proce-
dures. However, these empirical perspectives and mani-
festations of a rights-based approach belie the significant
inequalities and rights violations that arise in the case of
more complex health needs such as cancer. To shed
light on these issues, the paper focuses on the care path-
ways for breast and cervical cancer and explores access
and quality issues that arise at different points of the
care pathway and at different levels of the health system
with implications for the realization of the right to
health in Brazil.
Cancer is a growing health challenge in Brazil and the
annual number of deaths from cancer increased from
fewer than 100,000 in 1990 to around 200,000 in 2013,
representing 17% of all deaths [18]. Estimates of inci-
dence rate for 2018 show that with the exception
of non-melanoma skin cancer, breast (29.5%) and cer-
vical cancer (8.1%), together with colorectal cancer
(9.4%), are the most common cancers for women [19].
With the large anticipated increase in the number of
elderly in Brazil (the share of the population 60 years
and older is projected to increase from 10.2% in 2010 to
29.3% in 2050 [20]), the number of cancer cases is likely
to increase in the future. Furthermore, lawsuits related
to cancer care represent a significant part of litigation
and are a growing burden on the public purse [21–23].
It is therefore important to understand the performance
of SUS related to cancer care.
Previous literature focuses on measuring delays in can-
cer care and casual factors related to delays, primarily
for breast cancer [24–28]. Studies in various states show
that a large proportion of women with breast cancer are
diagnosed in late stages (II-IV) [24, 25, 27]. There is only
one national study to date that shows that 60% of cancer
patients received their diagnosis in a late stage (III or
IV) and only 15.9% of patients received treatment within
30 days, with an average wait time for radiotherapy of
113.4 days in 2010 [28]. Factors related to late diagnosis
include lack of patient awareness of cancer symptoms,
difficulty in obtaining access to diagnostics procedures
and specialist care [24, 26, 28] and deficiencies in pri-
mary care [28]. Simon et al. (2009) find that patients di-
agnosed with breast cancer in public institutions and in
the poorer north of the country were diagnosed at later
stages than those diagnosed in the private sector and in
the wealthier south of Brazil [27].
The paper contributes to this field of research by pro-
viding new analysis of administrative data in a number
of areas including waiting times, stage of diagnosis, and
measurements of productivity of cancer care by state
and region along the patient care pathway. In addition
to updating and expanding information in the only avail-
able national study from 2011 [28], it includes additional
information on prevention, screening and diagnosis,
various productivity measures, and analysis along
socio-economic dimensions where data permits. Based
on qualitative data from one state (Bahia) it sheds light
on the underlying factors behind the patterns observed
in the quantitative data. More broadly, the paper high-
lights the importance of health system analysis for ex-
posing, empirically, rights violations and ultimately the
distribution of health and ill health within and across
societies.
Methods
The paper focuses on the patient care pathways for breast
and cervical cancer and explores access and quality issues
that arise at different points of the care pathway and at
different levels of the health system with implications for
the realization of the right to health in Brazil.
The paper uses a mixed method with triangulation of na-
tional quantitative data and qualitative information from one
state (Bahia). The study is primarily based on analysis of ad-
ministrative data collected at both national and state levels
through cancer information systems (SISCOLO and SIS-
MAMA) and provider-based record systems.
SISCOLO and SISMAMA are national information sys-
tems for cervical and breast cancer and capture informa-
tion of results from both diagnostic and screening exams
(mammography and Pap smear) and pathological exams
of the breast and uterus (biopsy and surgical specimen).
These systems contain data from public providers, private
providers contracted by the SUS, states and municipalities.
They are comprehensive and reliable for publicly financed
health care in Brazil. However, SISCOLO and SISMAMA
do not cover an estimated 24.4% of the population with
private health insurance that access health care through
private providers and may therefore not adequately repre-
sent the more affluent states in the south (e.g. Federal Dis-
trict, Sao Paolo and Rio de Janeiro) where private health
insurance is high (above 20%) [29].
Official population-based parameters were used to es-
timate health service needs, with adjustments made to
account for the share of population covered by private
health providers. The parameters to estimate those
needs were based on official guidelines from the Minis-
try of Health (MOH), protocols for screening and treat-
ment and guidelines from the Brazilian National Cancer
Institute (INCA). Furthermore, national data from the
Outpatient Information System (SIA) provided data on
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procedures outside the hospital, while the Hospital Can-
cer Registry (HCR) was used to capture advanced diag-
nostics procedures, surgery and other treatment
procedures administered at the hospital level. Data on
infrastructure, health professionals and other elements
of the health system was obtained from the Registry of
health facilities (Cadastro Nacional de Estabelecimentos
de Saúde [CNES]) to analyze resources available for can-
cer care. Data from the national household survey (Pes-
quisa National por Amostra Domicililos [PNAD]) was
also used in the study. Data from HCR and CNES covers
all health facilities in the country, including privately
owned facilities, and is national representative. Data re-
lated to the delivery of cervical and breast cancer care
was collected from these various national administrative
systems and analyzed to characterize the realization of
the right to health for these two cancers in Brazil. A
summary description of national data sources is included
in Table 1.
To compliment the quantitative analysis and gain more
insights into the organization of cancer care, qualitative
data was collected in the state of Bahia. Bahia is an im-
portant state in northeast Brazil, which has a population
of 14.3 million people, with about 2.6 million (1.1 million)
citizens living below the moderate (extreme) poverty line.
Bahia was chosen after consultations with the MOH and
INCA because it represents an average performing state
in cancer care. Given the large size of the state it was ne-
cessary to narrow the geographical scope of the qualitative
study to one of Bahia’s nine health macro regions – the
east macro region. This region was selected because it
represents diversity both in terms of geography and econ-
omy and it is also where the state capital is located with
important cancer facilities that receive referrals from other
municipalities in the state. The east macro region has four
health regions (Camaçari, Cruz das almas, Salvador e
Santo and Antônio de Jesus) and 48 municipalities and is
home to 4.4 million people.
The study in Bahia was based on document analysis,
data from SUS information system, roundtable discus-
sions with health workers, structured interviews and
focus group discussions with staff working in health care
administration in the state, and semi-structured inter-
views and direct observations in health facilities. To bet-
ter understand the organization of cancer care and the
situation facing HWs, and identify challenges perceived
by the HWs, roundtable discussions with HWs were
conducted in the four health regions of focus.
Three roundtable discussions were held in each health
region with a total of 116 participants. Data collection
took place from July to September 2014. At least one
HW from each of the four areas (primary care, special-
ized care, regulation and control and information sys-
tems) was selected by the local manager to get diverse
Table 1 Summary description of national data sources
Description Comments
National information systems
for cervical and breast cancer
(SISCOLO/SISMAMA)
Information systems for cervical and breast cancer until
2012, when they started to be integrated in new cancer
information system (SISCAN). The information system is
fed by public providers, private providers contracted by
the SUS, states and municipalities. The system captures
data on the results of mammography, Pap smear exams
and pathological exams of the breast and uterus (biopsy
and surgical specimen).
The system suffers from delays in data entry and
incomplete data for some variables (with variation across
states).
Hospital Cancer Registry (HCR) Fed by hospitals and provides the basis for financial
transfers to providers. Captures advanced diagnostics
procedures, surgery and other treatment procedures that
are administered at the hospital level.
Given the link with financial transfers, data tends to be
more complete. Incentives for over-reporting exist but
are mitigated by control and auditing systems.
Outpatient Information System
(SIA)
Covers all procedures provided outside hospitals. Data
entered by providers. Provides the basis for financial
transfers to providers. Includes data on all outpatient
procedures.
Given the link with financial transfers, data tends to be
more complete. Incentives for over-reporting exist but
are mitigated by control and auditing systems.
National Household Sample
Survey (PNAD)
Is the national household sample survey conducted by
Brazilian Institute of Geography and Statistics since 1981.
The study draws on national representative data from the
health section.
2008 was the last time the health section of PNAD was
conducted. New data, including the health module, was
collected in 2018 but is not yet available.
Registry of health facilities
(CNES)
The system provides infrastructure information, type of
care provided, specialized services existing beds and the
number of health professionals in health facilities.
Although the CNES provides information on
infrastructure and HR, it does not contain data on
performance.
Parameters of needs The parameters to estimate the needs in the study have
been based on official guidelines from MOH described in
different ordinances (1101/2002 and others), protocols for
screening and treatment and guidelines from INCA.
MOH has calculated those parameters based on scientific
literature and previous years data.
Source: Authors
da Mota Almeida Peroni et al. International Journal for Equity in Health           (2019) 18:39 Page 4 of 15
perspectives. The questionnaires used during the round-
table discussions were designed in collaboration with
managers and technical staff from the MOH, INCA and
the State Heatlh Secretariat of Bahia (SESAB). The dis-
cussions were led by a Brazilian researcher and focused
on the following topics: policy context at the federal and
state level, the characterization of the network of cancer
care for the two cancers and system performance mea-
sures. A summary description of qualitative data col-
lected in the state of Bahia is included Additional file 1:
Table S1.
An innovative feature of the study was that realistic patient
cases were discussed, and specific questionnaires were used
to identify patient pathways and obstacles to accessing care
during roundtable discussions. To identify weaknesses in sys-
tem design and identify patient pathways, structured inter-
views (based on questionnaires focused on access, regulation,
contracting and primary as well as specialized care) and
focus-group discussions were undertaken with 17 partici-
pants from SESAB, the municipality of Salvador and the
State Center for Oncology. Direct observations and
semi-structured interviews at the facility level were con-
ducted in three facilities to identify how to get access to
screening tests, specialized appointments, etc. All interviews
and roundtable discussions were recorded, transcribed and
analyzed. Furthermore, administrative data was examined,
and a review of policies and programs was conducted. Equity
in access to care was explored and considered throughout
the analysis of the data. The preliminary results of the study
were also presented and discussed with policy makers in
Bahia and at the national level to confirm the results and
strengthen the rigor of the analysis. The study was approved
by the Research Ethics Committee of SESAB under No.
091582/2014, and participants agreed to be part of the study
by signing the Informed Consent Form.
Results
Drawing on the Organization for Economic
Co-operation and Development (OECD)’s frame-
work for elements of good cancer care [30] this
section is focused on the patient care pathway for
breast and cervical cancer. To set the stage, the
first section discusses the trends in breast and cer-
vical cancer in Brazil. Subsequent sections focus on
effective prevention, early detection and screening,
accurate diagnosis and staging and prompt access
to treatment. These represent elements of good
cancer care. The final section discusses resources
available for cancer care in Brazil.
Trends in breast and cervical cancer
The incidence of breast cancer in Brazil increased
between 1997 and 2013, while the incidence of cer-
vical cancer declined (Fig. 1). There are important
differences in trends across regions; the increase in
the breast cancer incidence was highest in the south
and central west. For cervical cancer, the incidence
decreased in all regions except the south, where inci-
dence has been stable. Per Fig. 2 mortality rate for
breast cancer increased from 7.5 to 14.3 deaths per
100,000 women between 1990 and 2015. Similarly,
although with less magnitude, the mortality rate for
cervical cancer also increased from 3.8 to 5.4 deaths
per 100,000 women for the same period. For breast
cancer, the mortality rates have increased in all age
groups (except between ages 10–14) with large in-
creases for women over 60 years old, and particularly
for those over 80 years old. Mortality rates for cer-
vical cancer decreased for women between 40 and
59 years old as well as for those age 10–14, however,
it increased again for women over 80 years old.
There are also notable regional differences in mor-
tality rates. For cervical cancer mortality rates have
increased rapidly in the poorest northern region. For
breast cancer mortality there are deteriorations in all
states within the second poorest region (central
west) and the poorest region (northeast), with the
highest increases. Relative cancer survival rates are
a good indicator of the performance of the health
system in cancer care. However, because there is no
population-based cancer registry in Brazil, survival
rates are not available.3 The absence of individual
data makes it impossible to determine if these two
cancers disproportionately affect certain population
groups or individuals.
A
Fig. 1 Cancer incidence in Brazil, 1997 and 2013
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Effective prevention
According to global estimates from the WHO, about
30–50% of cancer cases are preventable [31]. This
highlights the importance of prevention in effective
cancer control. For all cancers, important risk factors
for cancer are the prevalence of overweight, tobacco
smoking and alcohol consumption.
With regards to specific strategies to prevent cer-
vical cancer and breast cancer, SUS has intro-
duced Human papillomavirus (HPV) vaccination to
prevent cervical cancer, and genetic testing to better
screen for breast cancer. The Brazilian HPV
vaccination protocol is similar to those seen in other
countries with three doses of the vaccine offered
over a period of 5 years. The national coverage rate
for the second vaccine dose in 2014 was 59.3% of
the target population in the country [32]. Genetic
testing that assesses the risk of breast cancer
(BRCA1 and BRCA2) is currently only offered in univer-
sity hospitals or highly specialized centers to help identify
women with a family history of cancer who would benefit
from early screening. Population-based awareness cam-
paigns focused on breast, cervical and lung cancer have
been administered by MOH but on an irregular basis.
A
B
Fig. 2 Trends in breast and cervical cancer mortality rates/100,000 women
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Early detection and screening
If cancer can be diagnosed prior to the onset of symp-
toms, there are more treatment options and better sur-
vival prospects. Thus, screening is targeted at an
asymptomatic population to detect suggestive or precur-
sor lesions of cancer that can be referred for diagnostic
investigation. In Brazil, SUS offers population screening
for breast and cervical cancers free of charge. For cer-
vical cancer, Pap smear tests should be available to
women between 24 and 64 years old. The national guide-
lines recommend annual tests, but when there are two
consecutive negative tests, a woman can delay subse-
quent testing for 3 years. To detect breast cancer, annual
clinical breast exams are recommended for women over
40 years of age and mammography screening is recom-
mended for women between 50 and 69 years of age
every 3 years. These guidelines are in line with most
OECD countries, although the age bracket used to de-
fine the target group varies between countries [30].
To obtain a proxy for coverage rates of mammography
screening, the volume of mammography screening
exams completed is put in relation to population-based
estimates of individuals in need of mammography
exams. At the national level 65% of the need for screen-
ing is met. There are also large variations within the
country, where relatively wealthy states (Sao Paolo
[97%], Santa Catarina [94%] and Parana [88%]) have high
levels of coverage, in contrast to the worst performing
states that only cover a small percent of the population,
e.g. Amapa (0%) and Para (15%).
Interestingly, administrative data shows that almost half
(46%) of all mammogram screenings performed in SUS
are for women outside the target population.
Qualitative data from Bahia confirmed this finding and
shows that the state has a flexible targeting strategy:
“The MOH recommended age for screening of breast
cancer is 50 to 69 years; however, we see an increasing
number of cases detected below this age group. The
municipality of Salvador, and several other
municipalities, decided to be more flexible and
execute mammography screening after age 35. We
also changed the upper age limit, because life
expectancy is increasing for women, to include
women between 70 and 80 years old.” This is an
example of how health professionals do an implicit
prioritization of women outside the target population
as per stipulated in the national policy and in WHO
recommendations [33].
For cervical cancer, the volume of completed screening
exams is also well below the estimated need. At the na-
tional level, 54% of the estimated need of Pap smear
exams is met, with significant variation across states.
However, in most states the number of Pap smear cy-
tology samples collected exceeds the number of tests
completed, in some cases by a large margin. This is
likely related to issues with the quality of Pap smear
exams as described in detail below. Coverage of breast
and cervical cancer screening is lower in the poorest so-
cioeconomic groups. In national representative
survey-based data from the PNAD (Fig. 3a) three socio-
economic groups are defined: the poorest (III) living on
0–0.74 times the minimum salary; medium poor (II) liv-
ing on 0.75–1.99 times the minimum salary; and (I) 2 or
more times the minimum salary. Figure 3a shows that
almost half of the women in the lowest socioeconomic
group (48.4%, Confidence Interval [CI] [47.1, 49.6]) had
never received breast cancer screening, compared to
28.9% (CI [28.0, 29.8]) in the next to highest
socio-economic group (II) and 9.9% (CI [9.1, 10.7] in the
highest socio-economic group (I). The difference be-
tween access levels of socioeconomic groups is less in
cervical cancer screening. About 18.9% (CI [18.3–19.5]
of women in the poorest group had never received a Pap
smear, compared to 11.7% (CI [11.2–12.2] in group II
and 5.8% in group I (CI [5.3–6.2]). This finding is also
confirmed by state level data that shows a positive cor-
relation between state level mammography coverage and
the state’s human development index (HDI) (Fig. 3b).
This suggests that states that are better off economically
have higher coverage rates of breast cancer screening
and that groups with low socioeconomic status are sys-
tematically disadvantaged.
Accurate diagnosis and staging
The optimal time to diagnose breast and cervical cancer
is as soon as the cancer is detectable by screening. When
the cancer has already become symptomatic the thera-
peutic options are more limited. Early diagnosis of can-
cer requires careful clinical evaluation and laboratory
tests, especially biopsies, to confirm diagnosis and deter-
mine the stage of the tumor in order to determine treat-
ment options.
Using national level HCR data, stage of diagnosis for
breast and cervical cancer was estimated by state and re-
gion (Fig. 4a and b). Very few cases of breast (26%) and
cervical (39%) cancer are diagnosed at an early stage
(stage 0 or I), thereby reducing survival prospects of pa-
tients. The stage of diagnosis also varies substantially be-
tween different states, particularly for cervical cancer.
The relatively wealthy state of São Paulo provides con-
firmed diagnosis to 60% of women with cervical cancer
in stage 1, while the equivalent number for some of the
poorest states in the country (Alagoas, Acre and Ror-
aima) is 10%. Significant variations exist even within the
same region of Brazil. In the south, Rio Grande do Sul
and Santa Catarina diagnose 20% of cervical cancers in
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stage 1, while Paraná performs much better with 40% of
its cervical cancers diagnosed at the same time. Varia-
tions exist for breast cancer as well, although they are
smaller than for cervical cancer. Because there is no na-
tional cancer registry in Brazil, it is not possible to deter-
mine if certain population groups face additional
barriers for early diagnosis. But since poorer citizens are
disadvantaged as far as screening for breast and cervical
cancer is concerned, it is likely that such inequities per-
sist for the timing of diagnosis since screening programs
are meant to detect individuals with cancer risk.
Several health system bottlenecks were identified that
can contribute to late stage diagnosis including:
a) Low access to more sensitive diagnostics procedures:
An analysis of administrative data on the volume of
biopsy procedures relative to population-based esti-
mates of needs shows that only 35% of biopsy needs
are met in Brazil, with large variations between
states from 78% in Sao Paolo to 1% in Amazonas.
Coverage for Fine Needle Aspiration (FNA) for
diagnosis of breast cancer is similarly low at 27%.
b) No effective prioritization of patients with more
advanced cancer: 2014 data from SISMAMA shows
that the time interval between the request for a
specialist appointment and the completion of the
exam is almost the same for patients with a
mammogram that shows clinical symptoms and
patients that are asymptomatic. Thus, the system
does not give priority to patients that have more
advance stages of cancer.
c) Challenges regarding the quality of diagnostic exams
(both the collection process and analysis of results):
The number of Pap smear cytology samples
collected exceeds the number of tests completed, in
some cases by a large margin. At the national level,
collected samples represent 100% of the need, but
only 54% of these exams are completed. Thus, a
large share of collected samples are never
completed and may therefore need to be repeated.
This may be a result of how challenging it is to
obtain quality Pap smear exams or tests being lost
between the unit that collects the sample (often
primary care) and the entity that carries out the
diagnostics. This is also confirmed by the qualitative
data. Focus group discussions with HWs in Bahia
highlighted that poor clinical skills among HWs in
primary care affect the quality of diagnostics,
A
B
Fig. 3 Screening rates for women never tested by income (by minimum salary), 2003 and 2008
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particularly for Pap smear exams. One HW
explained: “With regard to cervical cancer there are
several issues. The first issue concerns HWs’
knowledge in carrying out Pap smear tests. We
observed that there were many unsatisfactory
samples and even after receiving training we haven’t
achieved the expected results.” There also seem to
be issues with task-shifting that may affect the qual-
ity of diagnosis: “It is important to point out that
currently most Pap smear exams are performed by
nurses in primary care, because the doctors who are
trained to do this test have not performed the exam.
Many of the nurses are recent graduates that are left
alone to try to figure out how to carry out these
exams.” Of the eleven patient cases collected in the
qualitative material from Bahia, four women had to
repeat the test because of the poor quality of exams.
Even if this small sample is not representative, the
extent of repeat exams raises concerns about the
quality of diagnostics procedures.
Prompt access to treatment
A waiting time legislation was introduced in 2014 that
guarantees treatment within 60 days of a confirmed diag-
nosis (based on the diagnosis being recorded in the
medical record).4 This is a long time compared to many
OECD countries – e.g. Chile (30 days for breast cancer
and 20 days for cervical cancer), Czech Republic (4
weeks) and England (31 days) [23]. Despite the waiting
time legislation, there is little systematic data on waiting
times in Brazil. Available data from HCR focuses on the
time between confirmed diagnosis and treatment and
suggests that waiting times are long and vary signifi-
cantly depending on the patient pathway. There are large
differences in waiting times between patients that are di-
agnosed through the recommended patient pathway, i.e.
A
B
Fig. 4 Stage of disease at diagnosis for breast cancer, by region, 2012
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diagnosis outside the hospital and referral to treatment
in the hospital, relative to patients that proceed directly
to the hospital for diagnosis and treatment (76 vs. 29
days for breast cancer and 82 vs. 29 days for cervical
cancer) (Fig. 5a and b). For patients that are diagnosed
outside the hospital, only eight states meet the waiting
time guarantee for cervical cancer patients (Acre, Ala-
goas, Ceara, Goias, Mato Grosso, Mato Grosso do Sul,
Piaui and Rio Grande do Norte) and only seven states
meet it for breast cancer patients (Ceara, the Federal
District, Espirito Santo, Goias, Piaui, Rio Grande do
Norte and Roraima). All states (except Sergipe for cer-
vical cancer) meet the waiting time guarantee of 60 days
between diagnosis and treatment when patients go dir-
ectly to the hospital. Thus, unless the patient turns to
the hospital for diagnosis, the waiting time guarantee is
not met, and this may explain why many patients skip
primary care and go directly to high-complexity units.
For both breast and cervical cancers, surgery is the
most common treatment when the cancer is detected
early, while radiotherapy and chemotherapy are used
more often for cancers diagnosed at later stages. Con-
sistent with the long waiting times and the advance stage
at which many women receive confirmed diagnoses,
2014 data from the HCR shows that in most municipal-
ities, a larger share of women start with chemotherapy
(82.2%) compared to surgery (50.6%). Previous research
shows that SUS users of breast cancer treatment services
travel 67 km to access treatment and 75% of displace-
ments between municipalities were closer than 151 km
away (Oliveira et al., 2011). Since treatments with e.g.
radiotherapy require frequent visits and there are long
distances for patients to travel, patients with cancer may
face logistical, financial or other challenges related to
their travel to the treatment unit. This was also con-
firmed in qualitative data that shows that the costs for
transport, accommodation, food and the opportunity
costs for not working are important barriers to access
cancer care and for the ability of patients to adhere to
treatment regimes.
Resources available for cancer care
At first glance, cancer care in Brazil is relatively well
resourced from an international perspective. Although
Brazil has fewer oncologists per million people (24) than
Sweden (61) and the United States (36), it is better
resourced in terms of the number of oncologists at a na-
tional level than many OECD countries such as France
(11) and Turkey (4) (OECD, 2013). Regarding technol-
ogy (Computerized Tomography [CT] scans and Mag-
netic Resonance Imaging [MRI] units per million
people), Brazil compares unfavorably with the United
States and South Korea but appears to have more tech-
nology for effective cancer care than many other middle-
and high-income countries such as the United Kingdom
and Mexico [30].
However, more detailed analysis reveals that
availability of equipment does not necessarily
translate into execution of services. Mammograms
examination capacity was estimated based on the
number of functional mammogram machines using
CNES. At the national level, estimated production
capacity exceeded the number of tests needed by
153%. Nevertheless, when considering the actual
utilization of these machines a different picture
emerges. Even if functional mammogram machines
exist, actual production is low across the country at
37% of capacity. This shows that there are other
constraints to increasing their use. These may
include the unavailability of qualified health workers
(radiology technicians, radiologists, and breast
clinics) and low maintenance of equipment/
machines.
There is also significant variation in the availability
of cancer care hospitals and oncologists across
regions in Brazil (Fig. 6a and b) where regions that
are better off have more resources. This may explain
why states/regions that are better off economically
(e.g. the southeast) have, e.g. higher coverage rates
of breast cancer screening as shown previously.
According to data from the national registry of
health institutions from 2013, Brazil has nearly 1.5
cancer hospital and 23 oncologists per million
people. However, regional averages range from 0.6
hospitals per million in the north to 2.3 per million
in the central west, and 7 oncologists per million in
the north to 32 per million in the southeast. Similar
disparities exist for other cancer care resources, such
as radiation therapy units, mammography units,
MRIs and CT scanners.
Data on government spending on cancer is limited.
Existing data (the Federal Audit Authority estimated
spending on cancer care to reach R$1.9 billion in
2010) only includes federal spending of hospital pro-
cedures linked to cancer and omits large amounts of
resources spent by states and municipalities [21].
Since an important factor for determining the size of
federal transfers to the state and municipal levels is
reported volume of cancer related procedures, it is
relevant to consider this indicator. Figure 7 shows
cancer related procedures increased between 9 and
22% over a two-year period (2011–2013). While these
estimates indicate that the cost for cancer care is in-
creasing in Brazil, available data do not permit a
more detailed analysis related to how resources are
being spent on cancer and fairness in financing.
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Discussion
Through this empirical assessment on equity and the
right to health along patient care pathways for breast
and cervical cancer in Brazil, it is shown that patients’
right to health is systematically violated at different
stages of the patient pathway.
In terms of early detection and screening, the analysis
reveals that at the national level only 65% and 54% of
the estimated need for mammography exams and Pap
smear exams respectively is met. There is large variation
across states in the extent to which screening needs for
breast and cervical cancer are met, with a tendency for
lower screening rates among the poorest groups of soci-
ety. Also, coverage rates of breast cancer screenings are
higher in states that are better off economically. Half of
mammography screenings is outside the target
A
B
Fig. 5 Days between diagnosis and treatment by location of diagnosis, by region, 2006–12 (averages)
da Mota Almeida Peroni et al. International Journal for Equity in Health           (2019) 18:39 Page 11 of 15
population, which may be caused by implicit
prioritization by health workers. This represents waste
and could potentially be harmful for women who could
get exposed to unnecessary radiation associated with
mammography. Quality of cervical cancer diagnostics
procedures is also a key concern: almost half (46%) of
collected samples for cervical cancer screening is never
completed, with consequences for patients, who face re-
peated tests and the stress that this implies. This is an
important contributor to low screening rates for cervical
cancer and raises concern about the training and know-
ledge of healthcare workers in this area, the coordination
between primary care providers and diagnostics pro-
viders and the quality of laboratory services.
The patients’ right to accurate diagnosis at an early
stage is also violated. The analysis confirms findings of
previous research [28] and shows that few cases of
breast cancer (26%) and cervical cancer (39%) are diag-
nosed at an early stage (stage 0 or I), thereby reducing
the survival prospects of patients. There is large vari-
ation in performance among states, particularly for early
diagnosis of cervical cancer, with a tendency of poorer
states faring worse than wealthy states in terms of early
diagnosis of the two cancers. Contributing factors to late
diagnosis include: challenges with the quality of diagnos-
tic exams for cervical cancer, low access to specialist
care and more sensitive diagnostics procedures (e.g. bi-
opsy and FNA) needed to confirm diagnosis and no ef-
fective prioritization of patients with advanced cancer in
confirmation of diagnosis.
While the right to prompt access to treatment is
now codified in the law that guarantees treatment
within 60 days of confirmed diagnosis, the study
shows that waiting times are not systematically col-
lected and monitored along the patient pathway.
Available data on the time between confirmed diag-
nosis and treatment suggests that waiting times are
long and depend on patients’ health-seeking behav-
iors. Waiting times are significantly longer for pa-
tients that follow the recommended patient pathway
and are diagnosed outside the hospital compared to
these who seek care directly at the hospital level and
receive both diagnosis and treatment in a hospital
(76 vs. 29 days for breast cancer and 82 vs. 29 days
for cervical cancer). For patients that go through the
recommended patient pathway, i.e. diagnosis outside
the hospital and referral to treatment in the hospital,
most of states have difficulty meeting the 60-day
waiting time guarantee stipulated in the law. While
data is not available on the socio-economic status of
patients for this variable, this finding may be a sign
that patients who are less informed and weak may
fare worse in a system where the recommended
pathway does not deliver on timely cancer treatment.
Consistent with the long waiting times and the ad-
vance stage at which many women receive confirmed
diagnosis, a larger share of women starts treatment
A B
Fig. 6 Resources for cancer care, by region, 2013
Fig. 7 Percentage increase in cancer treatment provision between
2011 and 2013, by services
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with chemotherapy (82.2%), the most common treat-
ment when the cancer is detected late, compared to
surgery (50.6%).
The paper shows how inequalities and rights violations
are the result of complex interactions of different parts
of the health system. At first glance, Brazil is relatively
well resourced from an international perspective as far
as oncologists per capita and availability of technology
for effective cancer care are concerned. However, de-
tailed analysis reveals that availability of equipment does
not necessarily translate into execution of services as e.g.
mammogram machines produce below capacity. The un-
equal distribution of oncologists and cancer hospitals
across the country are likely contributing to difficulties
and delays in physical access to cancer care observed in
the study. An in-depth capacity utilization assessment
could be useful to better understand existing capacity
constraints and monitor the use of equipment, facilities
and workforce dedicated to cancer care.
The paper also shows that important data points are
not available, e.g., the financing of cancer care. This
makes it difficult to draw firm conclusions on the health
system determinants for delivery of cancer care.
Yet, this type of detailed health system analysis, not
only exposes systemic inefficiencies along the patient
pathway, it also sheds light on how these inefficiencies
can be addressed to improve the right to health. For in-
stance, several measures can be taken to reduce waiting
times and provide prompter access to treatments. The
coordination of care between the primary care level and
the hospital level as well as units carrying out diagnos-
tics procedures could be improved by establishing clear
accountability frameworks and incentives for compliance
with agreed rules, fast-track pathways for patients with
advanced cancer could be introduced, and the use of
existing oncologists and cancer care hospitals could be
optimized and become more productive.
A key limitation of this study is the lack of data along
many dimensions such as race, sexuality and in some
cases socio-economic status. The analysis showed that
when such analysis could be completed, e.g. for coverage
of screening for breast and cervical cancer, SUS is not
fair, nor pro-poor. Investments in better data and more
systematic use of the same is therefore not just import-
ant to improving the management of the health system
but also to assess health equity in a specific area or to
monitoring rights violations. In the case of Brazil, a
population-based national cancer registry is critical to
better monitor the equity of cancer care. Patient-based
surveys, with questions related to cancer care, could also
be administered on a regular basis to determine how
well the system serves its citizens. Improved information
systems and use of data by HWs could enhance coordin-
ation of care and better data on e.g. waiting times and
treatment choices, would allow for health system per-
formance monitoring and national and international
benchmarking.
Judicialization is potentially an important tool to en-
sure effective coverage of interventions and the
maximization of equity in access to quality of care. With
this paper we argue that detailed health system analysis
along the patient pathway, with data that is disaggre-
gated along axes of gender, race, socio-economic status,
sexuality, and disability, can provide a powerful
complimentary tool in research on the right to health.
Health system research is valuable because it can pin-
point exactly how and where citizens’ right to health is
violated in practice and provide strategies to address
these issues. It can also be used to engage citizens and
patient groups and give them voice and evidence to
argue their case and thereby open doors for popular in-
put to shape health policy and hold states and other par-
ties accountable. Giving voice to vulnerable populations
and enabling them to change their conditions of vulner-
ability are critical pieces of the human rights-based ap-
proach [34]. As pointed out by Yamin (2014), health
systems are social institutions whose design and
organization depends on political struggles, which ultim-
ately determine what health outcomes they produce and
how health and ill health are distributed across citizens
in societies [8].
Conclusions
The study reveals that there are large variations between
states and patients, where the poorest states and patients
fare worse on key indicators related to breast and cer-
vical cancer care. More broadly, the paper shows the im-
portance of collecting data both on patient
characteristics and health system performance and carry
out detailed health system analysis for exposing, empir-
ically, rights violations and for identifying how they can
be addressed.
Endnotes
1Brazil has made significant progress in reducing in-
equality, the most commonly used inequality measure –
the Gini coefficient (the closer to 1, the more unequal) –
declined from 0.60 in 1990 to 0.51 in 2014 [35], but re-
gional inequalities remain. For instance, moderate pov-
erty was 15.1% and 17.6% in the north and northeast
regions, while the same number for the south and south-
east regions was 3.3% and 4.4%, respectively [36]
2Biehl et al. [37] challenge this research based on their
analysis of 1262 lawsuits from Rio Grande do Sul and
find that most patient-litigants are poor and older indi-
viduals. They conclude that there are regional differ-
ences that should not be fit into one singular narrative.
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3Existing cancer registries in Brazil record data from
specific capital cities, which is then used to estimate in-
cidence and mortality rates across a larger sample of the
population. However, this evidence presents a narrow
perspective of select population-based cancer registries
within a small segment of the population living in areas
of Brazil with higher economic status. This data is not
nationally representative and therefore problematic for
cross-country comparisons. The authors explored using
the data. However, the quality of the data was poor.
There were large discrepancies among the capitals in
terms of reporting information. Some of the registries
had not been fed for years. Furthermore, for the regis-
tries with more recent data, data management was
sometimes outsourced to third parties and without stan-
dardized guidelines for managing the data this led to in-
consistencies in data reporting. For all these reasons, the
authors decided to not use the data in this study.
4MOH Ordinance on cancer treatment waiting time
guarantee (Portaria No 876 de 16/5/2014).
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